BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 560 filers reported holding BIO-TECHNE CORP in Q2 2024. The put-call ratio across all filers is 0.33 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $2,745 | – | 39 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Summit Creek Advisors LLC | 143,734 | $14,611,000 | 3.07% |
| Brown Capital Management | 2,147,690 | $218,313,000 | 2.91% |
| STONE RUN CAPITAL, LLC | 42,925 | $4,364,000 | 2.62% |
| Select Equity Group, L.P. | 2,432,176 | $247,230,690,000 | 1.84% |
| MAIRS & POWER INC | 1,389,850 | $141,278,000 | 1.73% |
| Conestoga Capital Advisors, LLC | 256,213 | $26,044,000 | 1.57% |
| QUANTUM CAPITAL MANAGEMENT | 59,798 | $6,078,000 | 1.51% |
| First Light Asset Management, LLC | 38,202 | $3,883,000 | 1.48% |
| SEGALL BRYANT & HAMILL, LLC | 570,853 | $58,027,000 | 1.40% |
| RIVERBRIDGE PARTNERS LLC | 604,797 | $61,478,000 | 1.24% |